Collins, P., Liesner, R., Makris, M. orcid.org/0000-0001-7622-7939 et al. (7 more authors) (2018) Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia, 24 (3). pp. 344-347. ISSN 1351-8216
Abstract
Emicizumab is a bispecific antibody that activates FX to FXa in the absence of FVIII. It has been shown to reduce bleeding episodes in people with haemophilia A complicated by a FVIII inhibitor. Despite the protection against bleeds, some breakthrough bleeds are inevitable and these may require additional haemostatic treatment. Emicizumab has been associated with severe adverse events when co‐administered with activated prothrombin complex concentrate. To minimize the risk of adverse events, the UK Haemophilia Centre Doctors’ Organisation issues the following updated interim guidance to its Inhibitor Guidelines for managing patients receiving Emicizumab based on the limit published information available in February 2018.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2018 John Wiley & Sons Ltd. This is an author produced version of a paper subsequently published in Haemophilia. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | activated prothrombin complex concentrate; emicizumab; haemophilia; inhibitor; thrombosis; thrombotic angiopathy |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 08 May 2018 13:01 |
Last Modified: | 23 Nov 2020 14:37 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1111/hae.13495 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:130489 |